OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Biography:
Rab Prinjha currently leads the Epinova Epigenetics DPU in the Immuno-Inflammation therapy area (II-TA) and is co-chair of the GSK Biology Council. Prior to this he led the Target Progression department with responsibilities for target selection, validation and epigenetic compound characterisation along with coordinating academic collaborations. He joined Epinova from the II-virtual group which was responsible for implementing the externalisation and portfolio diversification strategy of the TA. Previously he led a Target Validation group in the Neurology CEDD focussed on neurodegeneration. In addition to advancing many programs while in Neurology he cloned a novel inhibitor of CNS regeneration called Nogo-A and led this program from gene cloning to Candidate Selection and into clinical trials. Rab joined GSK from academia including a post-doc in developmental neuroscience at Guy’s Hospital and PhD in molecular biology of the cell cytoskeleton at UCL.
